Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

11.26
-0.6700-5.62%
Post-market: 11.260.00000.00%19:58 EDT
Volume:2.87M
Turnover:33.32M
Market Cap:960.63M
PE:-6.45
High:12.26
Open:12.15
Low:11.07
Close:11.93
52wk High:25.77
52wk Low:7.24
Shares:85.31M
Float Shares:54.48M
Volume Ratio:3.43
T/O Rate:5.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.97
PE(LYR):-24.22

Loading ...

OverviewCompanyNewsFilings

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Dow Jones
·
Yesterday

Monte Rosa Therapeutics, - to Initiate Multiple Phase 2 Studies of Mrt-8102 in High Unmet Need Indications

THOMSON REUTERS
·
Yesterday

Monte Rosa Therapeutics Announces Positive Results for Mrt-8102 in Gforce-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of Ascvd in Subjects with Elevated CVD Risk

THOMSON REUTERS
·
Yesterday

Monte Rosa Shares Gain Ahead of Clinical Trial Review

Dow Jones
·
Yesterday

Monte Rosa Therapeutics Shares up 18% Premarket After H.c. Wainwright Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Yesterday

Monte Rosa Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $25

THOMSON REUTERS
·
Yesterday

Monte Rosa to Present Phase 1 Gforce-1 Data for MRT-8102 in Elevated Cardiovascular Risk Subjects

Reuters
·
Yesterday

Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush

Dow Jones
·
Sep 09

Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE

TIPRANKS
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

Monte Rosa Therapeutics to receive $50M milestone payment from Novartis

TIPRANKS
·
Sep 08

Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone

Reuters
·
Sep 08

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit

THOMSON REUTERS
·
Sep 08

Monte Rosa Grants Inducement Awards to New Hires, Including Options Priced at $14.31

Reuters
·
Sep 03

Monte Rosa Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 03

Monte Rosa Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 01
More